He reiterated at least 280M for 2024. For 2025 he brought up idea to segment therapeutics revenue, and to report a breakout segment you need at least 10% of revenues coming from that segment. So he is alluding to at least $30M in therapeutics revenue for 2025.. China approval expected this year and early next. Europe awaiting animal trials green light.